罗氟司特(Daliresp)在中国上市了吗?好购买吗？

Introduction: Roflumilast (Daliresp) has not yet been officially launched in China, so patients cannot directly purchase the drug in the Chinese market. Despite this, patients can still obtain the drug through some formal channels, but they need to choose carefully to avoid risks. At the same time, as a prescription drug, roflumilast requires special attention to the use of special groups of people when using it.

Is Roflumilast (Daliresp) available in China?

It is a phosphodiesterase-4 (PDE-4) inhibitor mainly used to treat chronic obstructive pulmonary disease (COPD). The drug was developed by the British company AstraZeneca and was first approved for marketing in the European Union in July 2010 and subsequently in the United States in March 2011. As of January 7, 2025, roflumilast (Daliresp) has not been officially launched in China, nor has it been included in China's medical insurance directory. Chinese patients cannot directly purchase the genuine product of this drug through formal domestic channels.

Is Roflumilast (Daliresp) easy to buy?

Since Roflumilast has not yet been officially launched in China, patients cannot directly purchase genuine drugs in the Chinese market. However, some patients may try to obtain the drug through overseas medical treatment, overseas drug purchase, or purchase assistance from medical service institutions. There are certain risks in these channels, such as difficulty in guaranteeing the authenticity of drugs, possible damage during transportation, legal compliance and other issues. Patients should be particularly cautious when choosing purchase channels and be sure to choose formal and reliable channels. At the same time, you need to know the production date, batch number, expiration date and other information of the drug before purchasing, and consult a professional doctor for advice.

Roflumilast (Daliresp) medication for special populations

As a prescription drug, special attention should be paid to special populations when using Roflumilast (Daliresp). Special populations include the elderly, children, pregnant women, lactating women, and patients with liver and kidney dysfunction.

Drugs for the Elderly

Due to reduced physiological functions, the elderly may have a reduced ability to metabolize and excrete drugs. Therefore, when using roflumilast, the dose needs to be adjusted according to the patient's specific condition and adverse reactions should be closely monitored.

Use in pregnant and nursing women

The use of roflumilast in pregnant and nursing women has not been fully studied. Therefore, the use of this drug should be avoided in these special groups. If it must be used, it should be done under the guidance of a doctor, and the health of the mother and baby should be closely monitored.

Drugs for patients with hepatic and renal insufficiency

Patients with hepatic and renal insufficiency may have a reduced ability to metabolize and excrete drugs, leading to accumulation of drugs in the body. Therefore, when using roflumilast, the dose needs to be adjusted according to the patient's liver and kidney function status, and adverse reactions must be closely monitored.